CD274 and neoplasm: Additionally, when combining PD‐L1 CPS and serological tumor biomarkers with these two sRNAs, the AUCs were 0.89 (95% CI; 0.79–1.00; Figure 3D) in the discovery cohort, 0.83 (95% CI; 0.70–0.96; Figure 3E) in the validation cohort, and 0.86 (95% CI: 0.78–0.94; Figure 3F) in the combined dataset.